Skip to content

Research on the Analysis of Rare Diseases Based on Genetic Data

Research on the Analysis of Rare Diseases Based on Genetic Data

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600127468
Enrollment
Unknown
Registered
2026-07-01
Start date
2026-07-01
Completion date
Unknown
Last updated
2026-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Genetic syndromes

Interventions

Case Group:None

Sponsors

Eye Hospital, Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Subjects who have undergone whole exome sequencing (WES) genetic testing in our outpatient clinic; 2. Subjects with complete ocular and systemic phenotypic data, including corrected visual acuity, refraction, intraocular pressure, fundus photography, corneal topography, slit-lamp examination, eye movement, as well as detailed medical records of systemic disease history, surgical history, family history, etc.

Exclusion criteria

Exclusion criteria: 1. Subjects who have previously undergone whole exome sequencing (WES) genetic testing and have been diagnosed with a genetic disease; 2. Subjects with incomplete clinical data that make genetic diagnosis difficult.

Design outcomes

Primary

MeasureTime frame
Prevalence of pathogenic variants in genetic syndromes identified through genotype-first opportunistic screening in candidates for refractive surgery;

Secondary

MeasureTime frame
Phenotypic characteristics of probands and their relatives carrying pathogenic variants (including mild ocular abnormalities such as nystagmus, wide interpupillary distance, strabismus, and history of systemic diseases and surgeries);

Countries

China

Contacts

Public ContactChen Shihao

Eye Hospital, Wenzhou Medical University

csh@eye.ac.cn+86 577 88068862

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jul 23, 2026